 |
|
Educational Overview Pulmonary arterial hypertension (PAH) is a rare disease with significant consequences, including serious functional impairment and premature death. If left untreated, PAH is rapidly fatal. Fortunately, over the past decade, the knowledge and understanding of this disease has greatly expanded. Furthermore, the availability of effective and more convenient oral and inhaled medications has allowed clinicians to better individualize therapy to meet patient treatment goals. Though there is no cure for PAH, effective treatment can significantly slow disease progression and clinical worsening. Given the serious nature of this disease and its rapid progression, optimal management approaches are essential. Optimal management of patients with PAH requires early detection and diagnosis followed by a patient-centered treatment plan. Given the complex and individualized nature of PAH therapy, pharmacists must have a full understanding of treatment algorithms, disease-specific therapies, and long-term monitoring recommendations based on evidence-based guidelines. As the armamentarium to treat PAH continues to expand, pharmacists must make efforts to stay informed of the latest finding in order to contribute to the optimal management of these patients. Target Audience This continuing pharmacy education activity is planned to meet the needs of pharmacists in a variety of practice settings, including large and small health systems, outpatient clinics, managed-care organizations, long-term care facilities, and academia. This program will target health-system pharmacists who are responsible for the safe and effective use of medications utilized for the treatment of patients with PAH. Learning Objectives Upon completing this activity, participants will be able to:
Educational Format This online activity is based on a series of live programs held in conjunction with State Societies of Health-System Pharmacists (SHPs) Annual Meetings.This activity is divided into five episodes:
Faculty
|
Pharmacists
In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), Center for Independent Healthcare Education requires all faculty members and planning committee with an opportunity to affect the content of a continuing education activity to disclose any relevent financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity. Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer. Planning Committee Members |
Disclosure of Financial Interest Summary Heather R. Bream-Rouwenhorst, PharmD, BCPS (Faculty/Planner) has no relevant financial relationships with commercial interests. Dr. Bream-Rouwenhorst does not intend to discuss the off-label use of a product. James C. Coons, PharmD (Faculty/Planner) has no relevant financial relationships with commercial interests. Dr. Coons does not intend to discuss the off-label use of a product.
Roberto F. Machado, MD (Faculty/Planner) has relevant financial relationships with commercial interests as follows: Rebekah L. Hanson, PharmD, BCPS, BCACP (Faculty/Planner) has no relevant financial relationships with commercial interests. Dr. Hanson does not intend to discuss the off-label use of a product. No other speakers, authors, planners or content reviewers have any relevant financial relationships to disclose. Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Cosponsorship
Commercial Support
Fee Hardware/Software Requirements Software/Hardware Connection Speed System Check Copyright Statement Privacy Policy http://www.vemcomeded.com/privacy.asp |
Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 2.0 contact hours (0.2 CEUs) of continuing pharmacy education credits for participating in this activity.
 |
||||
 |
 |
 |
 |
 |
  |
